US Patent

US12097284 — Mycophenolate oral suspension

Formulation · Assigned to Liqmeds Worldwide Ltd · Expires 2039-08-16 · 13y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a pharmaceutical composition in the form of a mycophenolate oral suspension.

USPTO Abstract

Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.

Drugs covered by this patent

Patent Metadata

Patent number
US12097284
Jurisdiction
US
Classification
Formulation
Expires
2039-08-16
Drug substance claim
No
Drug product claim
Yes
Assignee
Liqmeds Worldwide Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.